Analgesics
Antiandrogens
Azvudine
Bromhexine
Budesonide
Colchicine
Conv. Plasma
Curcumin
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Ivermectin
Lifestyle
Melatonin
Metformin
Minerals
Molnupiravir
Monoclonals
Naso/orophar..
Nigella Sativa
Nitazoxanide
Paxlovid
Quercetin
Remdesivir
Thermotherapy
Vitamins
More

Other
Feedback
Home
Top
Abstract
All ivermectin studies
Meta analysis
 
Feedback
Home
next
study
previous
study
c19ivm.org COVID-19 treatment researchIvermectinIvermectin (more..)
Melatonin Meta
Metformin Meta
Azvudine Meta
Bromhexine Meta Molnupiravir Meta
Budesonide Meta
Colchicine Meta
Conv. Plasma Meta Nigella Sativa Meta
Curcumin Meta Nitazoxanide Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Quercetin Meta
Fluvoxamine Meta Remdesivir Meta
Hydroxychlor.. Meta Thermotherapy Meta
Ivermectin Meta

All Studies   Meta Analysis    Recent:   

Two Years of Experience and Methodology of Korean COVID-19 Living Clinical Practice Guideline Development

Choi et al., Journal of Korean Medical Science, doi:10.3346/jkms.2023.38.e195
Jun 2023  
  Post
  Facebook
Share
  Source   PDF   All Studies   Meta AnalysisMeta
Ivermectin for COVID-19
4th treatment shown to reduce risk in August 2020
 
*, now known with p < 0.00000000001 from 102 studies, recognized in 22 countries.
No treatment is 100% effective. Protocols combine complementary and synergistic treatments. * >10% efficacy in meta analysis with ≥3 clinical studies.
4,000+ studies for 60+ treatments. c19ivm.org
Review of the development of COVID-19 treatment guidelines in Korea. Authors claim "continuous evidence updates" and "living recommendations", however the ivermectin recommendation has not been updated since Dec 1, 2021 (over 860 days) neca.re.kr. The review shows positive results without statistical significance, claiming "insufficient evidence". However, the review only includes 8 of 102 studies (49 RCTs). Authors include one retracted study Samaha, and the other studies included are biased towards lower quality studies, e.g., see issues with Abd-Elsalam, López-Medina, Ravikirti, Vallejos.
Choi et al., 12 Jun 2023, South Korea, peer-reviewed, 24 authors. Contact: yhwanseok@naver.com, hohouno@naver.com.
This PaperIvermectinAll
Two Years of Experience and Methodology of Korean COVID-19 Living Clinical Practice Guideline Development
Miyoung Choi, Hyeon-Jeong Lee, Su-Yeon Yu, Jimin Kim, Jungeun Park, Seungeun Ryoo, Inho Kim, Dong Ah Park, Young Kyung Yoon, Joon-Sung Joh, Sunghoon Park, Ki Wook Yun, Chi-Hoon Choi, Jae-Seok Kim, Sue Shin, Hyun Kim, Kyungmin Huh, In-Seok Jeong, Soo-Han Choi, Sung Ho Hwang, Hyukmin Lee, Dong Keon Lee, MD Hwan Seok Yong, MD Ho Kee Yum
Journal of Korean Medical Science, doi:10.3346/jkms.2023.38.e195
Background: In Korea, during the early phase of the coronavirus disease 2019 (COVID-19) pandemic, we responded to the uncertainty of treatments under various conditions, consistently playing catch up with the speed of evidence updates. Therefore, there was high demand for national-level evidence-based clinical practice guidelines for clinicians in a timely manner. We developed evidence-based and updated living recommendations for clinicians through a transparent development process and multidisciplinary expert collaboration. Methods: The National Evidence-based Healthcare Collaborating Agency (NECA) and the Korean Academy of Medical Sciences (KAMS) collaborated to develop trustworthy Korean living guidelines. The NECA-supported methodological sections and 8 professional medical societies of the KAMS worked with clinical experts, and 31 clinicians were involved annually.
SUPPLEMENTARY MATERIALS Supplementary Table 1 COVID-19 severity classification system and definitions for adult patients Click here to view Supplementary Table 2 Korean COVID-19 severity classification system and definitions for adult patients Click here to view Supplementary Table 3 Coronavirus disease 2019 severity classification system and definitions for pediatric patients Click here to view Supplementary Table 4 Level of evidence and meaning based on Grading of Recommendations Assessment Development and Evaluation approach Click here to view Supplementary Table 5 Grade of recommendation based on the Grading of Recommendations Assessment Development and Evaluation approach Click here to view Supplementary Table 6 Summary of medication treatments recommendations (a total of 16 recommendations can be summarized as follows) Click here to view Supplementary Table 7 Summary of recommendations for respiratory critical care (a total of six clinical questions can be summarized as follows) Click here to view Supplementary Table 8 Summary of recommendations for pediatric care (a total of four clinical questions can be summarized as follows) Click here to view Supplementary Table 9 Summary of recommendation for emergency care (recommendation for one clinical question can be summarized as follows) Click here to view Supplementary Table 10 Summary of recommendations for diagnostic test (recommendation for one clinical question can be summarized as..
References
Akl, Meerpohl, Elliott, Kahale, Schünemann, Living systematic reviews: 4. living guideline recommendations, J Clin Epidemiol, doi:10.1016/j.jclinepi.2017.08.009
Cheyne, Navarro, Buttery, Chakraborty, Crane et al., Methods for living guidelines: early guidance based on practical experience. Paper 3: selecting and prioritising questions for living guidelines, J Clin Epidemiol
Cheyne, Navarro, Hill, Mcdonald, Tunnicliffe et al., Methods for living guidelines: early guidance based on practical experience, J Clin Epidemiol, doi:10.1016/j.jclinepi.2022.12.024
Choi, Kim, Lee, Current status of clinical practice guidelines in Korea, J Korean Med Sci, doi:10.3346/jkms.2021.36.e35
Core, R: A Language and Environment for Statistical Computing
Djulbegovic, Guyatt, Evidence-based medicine in times of crisis, J Clin Epidemiol, doi:10.1016/j.jclinepi.2020.07.002
Gandhi, Lynch, Rio, Mild or moderate COVID-19, N Engl J Med, doi:10.1056/NEJMcp2009249
Guyatt, Oxman, Kunz, Atkins, Brozek et al., GRADE guidelines: 2. framing the question and deciding on important outcomes, J Clin Epidemiol, doi:10.1016/j.jclinepi.2010.09.012
Hewitt, Mcdonald, Poole, White, Turner et al., Weekly updating of guideline recommendations was feasible: the Australian National COVID-19 clinical evidence taskforce, J Clin Epidemiol
Higgins, Altman, Gøtzsche, Jüni, Moher et al., The Cochrane Collaboration's tool for assessing risk of bias in randomised trials, BMJ, doi:10.1136/bmj.d5928
Hill, English, Campbell, Mcdonald, Pattuwage et al., Feasibility of national living guideline methods: The Australian Stroke Guidelines, J Clin Epidemiol, doi:10.1016/j.jclinepi.2021.11.020
Kim, Park, Lee, Seo, Sheen et al., Testing a tool for assessing the risk of bias for nonrandomized studies showed moderate reliability and promising validity, J Clin Epidemiol
Kim, Ryoo, Huh, Joo, Kim et al., Revised Korean Society of Infectious Diseases/ National Evidence-based Healthcarea Collaborating Agency guidelines on the treatment of patients with COVID-19, Infect Chemother, doi:10.3947/ic.2021.0303
Kim, Sung, Lee, Kim, Shin et al., Clinical performance of rapid and point-of-care antigen tests for SARS-CoV-2 variants of concern: a living systematic review and meta-analysis, Viruses, doi:10.3390/v14071479
Kowalski, Morgan, Falavigna, Florez, Etxeandia-Ikobaltzeta et al., Development of rapid guidelines: 1. systematic survey of current practices and methods, Health Res Policy Syst, doi:10.1186/s12961-018-0327-8
Lamontagne, Agarwal, Rochwerg, Siemieniuk, Agoritsas et al., A living WHO guideline on drugs for COVID-19, BMJ, doi:10.1136/bmj.m3379
Lamontagne, Stegemann, Agarwal, Agoritsas, Siemieniuk et al., A living WHO guideline on drugs to prevent covid-19, BMJ, doi:10.1136/bmj.n526
Lee, Kim, Choi, Choi, Joh et al., Early intubation and clinical outcomes in patients with severe COVID-19: a systematic review and meta-analysis, Eur J Med Res, doi:10.1186/s40001-022-00841-6
Lee, Kim, Choi, Choi, Joh et al., Efficacy and safety of prone position in COVID-19 patients with respiratory failure: a systematic review and meta-analysis, Eur J Med Res, doi:10.1186/s40001-022-00953-z
Pottie, Smith, Matthews, Santesso, Magwood et al., A multistakeholder development process to prioritize and translate COVID-19 health recommendations for patients, caregivers and the public. A case study of the COVID-19 recommendation map, J Clin Epidemiol, doi:10.1016/j.jclinepi.2022.04.012
Pubmed | Crossref, None, doi:10.1016/j.jclinepi.2012.09.016
Pubmed | Crossref, None, doi:10.1016/j.jclinepi.2023.02.019
Pubmed | Crossref, None, doi:10.1080/22221751.2022.2059405
Ryoo, Koh, Yu, Choi, Huh et al., Clinical efficacy and safety of interferon (type I and type III) therapy in patients with COVID-19: a systematic review and meta-analysis of randomized controlled trials, PLoS One, doi:10.1371/journal.pone.0272826
Whiting, Rutjes, Westwood, Mallett, Deeks et al., QUADAS-2: a revised tool for the quality assessment of diagnostic accuracy studies, Ann Intern Med, doi:10.7326/0003-4819-155-8-201110180-00009
Yamakawa, Yamamoto, Terayama, Hashimoto, Ishihara et al., Japanese rapid/living recommendations on drug management for COVID-19: updated guidelines, Acute Med Surg, doi:10.1002/ams2.706
Yamakawa, Yamamoto, Terayama, Hashimoto, Ishihara et al., Japanese rapid/living recommendations on drug management for COVID-19: updated guidelines, Acute Med Surg, doi:10.1002/ams2.789
Yu, Koh, Choi, Ryoo, Huh et al., Clinical efficacy and safety of interleukin-6 receptor antagonists (tocilizumab and sarilumab) in patients with COVID-19: a systematic review and meta-analysis, Emerg Microbes Infect
Loading..
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit